Can Qiju Dihuang Wan and Guipi Wan Be Taken Together?

Qiju Dihuang Wan and Guipi Wan are two widely used traditional Chinese herbal formulas, each with distinct therapeutic indications and pharmacological profiles. Qiju Dihuang Wan—comprising Rehmannia glutinosa (Shu Di Huang), Cornus officinalis (Shan Zhu Yu), Dioscorea opposita (Shan Yao), Alisma orientale (Ze Xie), Poria cocos (Fu Ling), Moutan cortex (Mu Dan Pi), Chrysanthemum morifolium (Ju Hua), and Lycium barbarum (Gou Qi Zi)—is primarily indicated for liver-kidney yin deficiency syndrome, commonly presenting with symptoms such as blurred vision, photophobia, dry eyes, dizziness, tinnitus, and lower back soreness.

In contrast, Guipi Wan—formulated with Astragalus membranaceus (Huang Qi), Codonopsis pilosula (Dang Shen), Atractylodes macrocephala (Bai Zhu), Poria cocos (Fu Ling), Ziziphus jujuba (Suan Zao Ren), Polygala tenuifolia (Yuan Zhi), Longan aril (Long Yan Rou), Glycyrrhiza uralensis (Gan Cao), Angelica sinensis (Dang Gui), and Zingiber officinale (Sheng Jiang)—targets heart-spleen deficiency, particularly when accompanied by qi and blood deficiency. Clinical manifestations include fatigue, poor appetite, palpitations, insomnia, forgetfulness, and spontaneous sweating.

From a traditional Chinese medicine (TCM) perspective, concurrent use of these two formulas may be clinically justified in patients exhibiting overlapping patterns—specifically, those with both liver-kidney yin deficiency and heart-spleen qi-blood deficiency. However, this combination requires careful pattern differentiation by a qualified TCM practitioner, as inappropriate pairing could lead to therapeutic redundancy or imbalance—for example, excessive tonification without addressing underlying dampness or heat.

Modern pharmacovigilance data do not report major herb–herb interactions between the constituent herbs of Qiju Dihuang Wan and Guipi Wan. Nevertheless, safety considerations remain: both formulas contain multiple bioactive compounds that may influence cytochrome P450 enzyme activity or affect coagulation pathways. Patients taking anticoagulants, antihypertensives, or hypoglycemic agents should be monitored closely. Additionally, individuals with diabetes, hypertension, or chronic kidney disease should consult a healthcare provider before initiating either formula—or their combination—due to potential effects on glucose metabolism, blood pressure regulation, and renal clearance.

Clinical decision-making must prioritize individualized assessment over fixed protocols. While empirical use occurs in practice, evidence supporting synergistic efficacy of this specific combination remains limited to case reports and observational studies—not robust randomized controlled trials. Therefore, integrative practitioners should weigh potential benefits against risks, document rationale, and reassess outcomes regularly.